RxDoctor Payments DataLook up a doctor →

Hugh Durrence, MD

Family Medicine · Charleston, SCNPI 1750551206

Payments from drug & device makers

$933,569in general payments, 2019–2025

Across 784 payments — averaging $1190.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$177K
  • Ironwood Pharmaceuticals, Inc$175K
  • Amgen$173K
  • GSK$133K
  • AbbVie$91K
  • Genentech, Inc.$66K
  • plus $118K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer58$177,186
Ironwood Pharmaceuticals, Inc62$174,520
Amgen(2 entities)50$173,305
GSK44$133,456
AbbVie(2 entities)105$91,031
Genentech, Inc.30$65,774
Janssen Research & Development, LLC23$29,336
Vertex2$27,900
Sagent Pharmaceuticals2$17,900
AstraZeneca56$15,084
Verona Pharma, Inc.2$9,700
Chiesi USA, Inc.2$6,200
Sekisui Diagnostics LLC2$3,900
Johnson & Johnson38$1,235
Novo Nordisk38$824
Lilly USA, LLC34$768
Bayer25$482
CMS Imaging, Inc.6$466
Novartis6$407
Exact Sciences17$406
Tosoh Bioscience, Inc.1$233
Abbott11$232
Biogen9$213
Amarin Pharma, Inc.9$211
Takeda Pharmaceuticals U.S.A., Inc.11$188
Seqirus USA Inc11$171
Shield Therapeutics Inc4$145
Boston Scientific8$143
Noven Therapeutics, LLC6$138
Averitas Pharma Inc.2$104
Teva Pharmaceuticals USA, Inc.7$96
Renalytix AI, Inc.5$94
Boehringer Ingelheim6$91
Sanofi-aventis U.S. LLC5$90
Philips North America LLC4$89
Biohaven Pharmaceuticals, Inc.5$89
Insulet Corporation5$86
Lundbeck LLC4$78
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$75
Jazz Pharmaceuticals Inc.4$75
Biohaven Pharmaceutical Holding Company Ltd.4$71
Shire North American Group Inc5$70
Esperion Therapeutics, Inc.5$69
Vanda Pharmaceuticals Inc.4$68
Harmony Biosciences LLC4$67
Xeris Pharmaceuticals, Inc.3$61
Novavax Inc2$53
Idorsia Pharmaceuticals US Inc3$44
Surgalign Spine Technologies, Inc.2$44
Astellas Pharma US Inc2$41
Baxter Healthcare2$39
Alnylam Pharmaceuticals Inc.2$38
Sunovion Pharmaceuticals Inc.2$38
Edwards Lifesciences1$35
Aytu Biopharma, Inc.2$35
Avanir Pharmaceuticals, Inc.2$30
Merck2$30
Eisai Inc.2$29
Kowa Pharmaceuticals America, Inc.2$26
Dexcom, Inc.1$25

How this compares

$933,569 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina →

Medicare billing

Part B allowed, 2024
$197,455
Medicare patients
463
Services billed
4,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →